Hydroxyurea for Children with Sickle Cell Disease

Hematology/Oncology Clinics of North America

Volumn 24, Issue 1, 2010, Pages 199-214

  Heeney, Matthew M ^a,b   Ware, Russell E ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antisickling agents; Child; Human; Hydroxyurea; Sickle cell anemia

Indexed keywords

HEMOGLOBIN; HEMOGLOBIN F; HYDROXYUREA; PLACEBO; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; BLOOD TOXICITY; BLOOD TRANSFUSION; BLOOD VESSEL OCCLUSION; BONE MARROW SUPPRESSION; CEREBROVASCULAR ACCIDENT; CHILD; CHILDHOOD DISEASE; CHRONIC DISEASE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CYTOTOXICITY; DEVELOPMENTAL DISORDER; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG STABILITY; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GROWTH DISORDER; HAIR DISEASE; HEMOGLOBINOPATHY; HEMOLYSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPIGMENTATION; IRON CHELATION; IRON OVERLOAD; LEUKOCYTE COUNT; LIVER TOXICITY; MORNING DOSAGE; MULTIPLE ORGAN FAILURE; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEOPLASM; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PAIN; PANCYTOPENIA; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHLEBOTOMY; POLYCYTHEMIA VERA; PRIMARY PREVENTION; PRIORITY JOURNAL; RETICULOCYTE COUNT; REVIEW; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SICKLE CELL ANEMIA; SIDE EFFECT; SINGLE DRUG DOSE; SKIN DISEASE; SPERMATOGENESIS; SPLEEN FUNCTION; STOMACH PAIN; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREATMENT PLANNING; VASCULAR DISEASE; WEIGHT GAIN;

ANEMIA, SICKLE CELL; CHILD; HUMANS; HYDROXYUREA; MAXIMUM TOLERATED DOSE; RISK ASSESSMENT;

EID: 74749106742     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.11.002     Document Type: Review

References (72)

1. Platt O.S., Thorington B.D., Brambilla D.J., et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 325 1 (1991) 11-16
2. Steinberg M.H., Rosenstock W., Coleman M.B., et al. Effects of thalassemia and microcytosis on the hematologic and vasoocclusive severity of sickle cell anemia. Blood 63 6 (1984) 1353-1360
3. Baum K.F., Dunn D.T., Maude G.H., et al. The painful crisis of homozygous sickle cell disease. A study of the risk factors. Arch Intern Med 147 7 (1987) 1231-1234
4. Phillips Jr. G., Coffey B., Tran-Son-Tay R., et al. Relationship of clinical severity to packed cell rheology in sickle cell anemia. Blood 78 10 (1991) 2735-2739
5. Powars D.R. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 28 3 (1991) 202-208
6. Platt O.S., Brambilla D.J., Rosse W.F., et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330 23 (1994) 1639-1644
7. Charache S. Fetal hemoglobin, sickling, and sickle cell disease. Adv Pediatr 37 (1990) 1-31
8. Wood W.G. Increased HbF in adult life. Baillieres Clin Haematol 6 1 (1993) 177-213
9. Serjeant G.R. Fetal haemoglobin in homozygous sickle cell disease. Clin Haematol 4 1 (1975) 109-122
10. Wood W.G., Stamatoyannopoulos G., Lim G., et al. F-cells in the adult: normal values and levels in individuals with hereditary and acquired elevations of Hb F. Blood 46 5 (1975) 671-682
11. Watson J., Stahman A.W., and Bilello F.P. Significance of paucity of sickle cells in newborn negro infants. Am J Med Sci 215 (1948) 419-423
12. Steinberg M.H. Compound heterozygous and other hemoglobinopathies. In: Steinberg M.H., Forget B.G., and Higgs D.R. (Eds). Disorders of hemoglobin: genetics, pathophysiology, and clinical management (2001), Cambridge University Press, Cambridge (UK) 786-810
13. Odenheimer D.J., Sarnaik S.A., Whitten C.F., et al. The relationship between fetal hemoglobin and disease severity in children with sickle cell anemia. Am J Med Genet 27 3 (1987) 525-535
14. Gladwin M.T., Sachdev V., Jison M.L., et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 350 9 (2004) 886-895
15. Powars D.R., Schroeder W.A., Weiss J.N., et al. Lack of influence of fetal hemoglobin levels or erythrocyte indices on the severity of sickle cell anemia. J Clin Invest 65 3 (1980) 732-740
16. Powars D.R., Weiss J.N., Chan L.S., et al. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?. Blood 63 4 (1984) 921-926
17. Leikin S.L., Gallagher D., Kinney T.R., et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 84 3 (1989) 500-508
18. Ley T.J., DeSimone J., Noguchi C.T., et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62 2 (1983) 370-380
19. DeSimone J., Koshy M., Dorn L., et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood 99 11 (2002) 3905-3908
20. Koshy M., Dorn L., Bressler L., et al. 2-Deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 96 7 (2000) 2379-2384
21. Saunthararajah Y., Hillery C.A., Lavelle D., et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood 102 12 (2003) 3865-3870
22. Atweh G.F., Sutton M., Nassif I., et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93 6 (1999) 1790-1797
23. Dover G.J., Brusilow S., and Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 84 1 (1994) 339-343
24. Resar L.M., Segal J.B., Fitzpatric L.K., et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol 24 9 (2002) 737-741
25. Sher G.D., Ginder G.D., Little J., et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med 332 24 (1995) 1606-1610
26. Davies S.C., and Gilmore A. The role of hydroxyurea in the management of sickle cell disease. Blood Rev 17 2 (2003) 99-109
27. Halsey C., and Roberts I.A. The role of hydroxyurea in sickle cell disease. Br J Haematol 120 2 (2003) 177-186
28. Lori F., Foli A., Groff A., et al. Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms. AIDS 19 11 (2005) 1173-1181
29. Dover G.J., Humphries R.K., Moore J.G., et al. Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood 67 3 (1986) 735-738
30. Platt O.S., Orkin S.H., Dover G., et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 74 2 (1984) 652-656
31. Charache S., Dover G.J., Moyer M.A., et al. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69 1 (1987) 109-116
32. Charache S., Dover G.J., Moore R.D., et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 79 10 (1992) 2555-2565
33. Letvin N.L., Linch D.C., Beardsley G.P., et al. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 310 14 (1984) 869-873
34. Gladwin M.T., Shelhamer J.H., Ognibene F.P., et al. Nitric oxide donor properties of hydroxyurea in patients with sickle cell disease. Br J Haematol 116 2 (2002) 436-444
35. Huang J., Yakubu M., Kim-Shapiro D.B., et al. Rat liver-mediated metabolism of hydroxyurea to nitric oxide. Free Radic Biol Med 40 9 (2006) 1675-1681
36. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 332 20 (1995) 1317-1322
37. Kinney T.R., Helms R.W., O'Branski E.E., et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 94 5 (1999) 1550-1554
38. Wang W.C., Helms R.W., Lynn H.S., et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study. J Pediatr 140 2 (2002) 225-229
39. Ware R.E., Eggleston B., Redding-Lallinger R., et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99 1 (2002) 10-14
40. Scott J.P., Hillery C.A., Brown E.R., et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 128 6 (1996) 820-828
41. Jayabose S., Tugal O., Sandoval C., et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr 129 4 (1996) 559-565
42. Ferster A., Vermylen C., Cornu G., et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88 6 (1996) 1960-1964
43. de Montalembert M., Belloy M., Bernaudin F., et al. Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol 19 4 (1997) 313-318
44. Ferster A., Tahriri P., Vermylen C., et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97 11 (2001) 3628-3632
45. Zimmerman S.A., Schultz W.H., Davis J.S., et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103 6 (2004) 2039-2045
46. Wang W.C., Wynn L.W., Rogers Z.R., et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139 6 (2001) 790-796
47. Hankins J.S., Ware R.E., Rogers Z.R., et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood 106 7 (2005) 2269-2275
48. Hankins J.S., Helton K.J., McCarville M.B., et al. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 50 2 (2008) 293-297
49. Fitzhugh C.D., Wigfall D.R., and Ware R.E. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 45 7 (2005) 982-985
50. Saad S.T., Lajolo C., Gilli S., et al. Follow-up of sickle cell disease patients with priapism treated by hydroxyurea. Am J Hematol 77 1 (2004) 45-49
51. Maples B.L., and Hagemann T.M. Treatment of priapism in pediatric patients with sickle cell disease. Am J Health Syst Pharm 61 4 (2004) 355-363
52. Singh S, Koumbourlis A, Aygun B. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. Pediatr Blood Cancer. [Epub ahead of print].
53. Kratovil T., Bulas D., Driscoll M.C., et al. Hydroxyurea therapy lowers TCD velocities in children with sickle cell disease. Pediatr Blood Cancer 47 7 (2006) 894-900
54. Zimmerman S.A., Schultz W.H., Burgett S., et al. Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood 110 3 (2007) 1043-1047
55. Ware R.E., Zimmerman S.A., and Schultz W.H. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood 94 9 (1999) 3022-3026
56. Sumoza A., de Bisotti R., Sumoza D., et al. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA). Am J Hematol 71 3 (2002) 161-165
57. Ware R.E., Zimmerman S.A., Sylvestre P.B., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145 3 (2004) 346-352
58. ClinicalTrials.gov. Stroke with transfusions changing to hydroxyurea (SWiTCH). Available at: http://clinicaltrials.gov/ct2/show/NCT00122980.
59. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 289 13 (2003) 1645-1651
60. Pata O., Tok C.E., Yazici G., et al. Polycythemia vera and pregnancy: a case report with the use of hydroxyurea in the first trimester. Am J Perinatol 21 3 (2004) 135-137
61. Byrd D.C., Pitts S.R., and Alexander C.K. Hydroxyurea in two pregnant women with sickle cell anemia. Pharmacotherapy 19 12 (1999) 1459-1462
62. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease. Intern Med J 37 3 (2007) 190-192
63. Masood J., Hafeez A., Hughes A., et al. Hydroxyurea therapy: a rare cause of reversible azoospermia. Int Urol Nephrol 39 3 (2007) 905-907
64. ClinicalTrials.gov. Long term effects of hydroxyurea therapy in children with sickle cell disease. Available at: http://clinicaltrials.gov/ct2/show/NCT00305175.
65. Schultz W.H., and Ware R.E. Malignancy in patients with sickle cell disease. Am J Hematol 74 4 (2003) 249-253
66. Miller S.T., Sleeper L.A., Pegelow C.H., et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med 342 2 (2000) 83-89
67. NIH. National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease; 2008. Available at: http://consensus.nih.gov/2008/Sickle%20Cell%20Draft%20Statement%2002-27-08.pdf.
68. Thornburg C.D., Dixon N., Burgett S., et al. Efficacy of hydroxyurea to prevent organ damage in young children with sickle cell anemia. Blood 110 11 (2007) 3386
69. Yan J.H., Ataga K., Kaul S., et al. The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. J Clin Pharmacol 45 4 (2005) 434-445
70. Heeney M.M., Whorton M.R., Howard T.A., et al. Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol 26 3 (2004) 179-184
71. Bridges K.R., Barabino G.D., Brugnara C., et al. A multiparameter analysis of sickle erythrocytes in patients undergoing hydroxyurea therapy. Blood 88 12 (1996) 4701-4710
72. Becker M.H., and Maiman L.A. Sociobehavioral determinants of compliance with health and medical care recommendations. Med Care 13 1 (1975) 10-24